CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study

We conducted a nested case control study of 178 incident breast cancer cases and 356 controls in the Atherosclerosis Risk in Communities study. We evaluated the association between breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 ge...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2004-04, Vol.207 (2), p.183-189
Main Authors: Thyagarajan, Bharat, Brott, Marcia, Mink, Pamela, Folsom, Aaron R, E. Anderson, Kristin, Oetting, William Starr, Gross, Myron
Format: Article
Language:English
Subjects:
Aromatase - genetics
Aryl Hydrocarbon Hydroxylases - genetics
Breast cancer
Breast Neoplasms - enzymology
Breast Neoplasms - epidemiology
Breast Neoplasms - genetics
Case-Control Studies
Cohort Studies
CYP19
CYP1B1
Cytochrome P-450 CYP1B1
DNA Primers - chemistry
DNA, Neoplasm - genetics
Estrogen metabolism
Estrogens
Female
Gene Frequency
Genotype
Humans
Incidence
Introns
Longitudinal Studies
Male
Microsatellite Repeats - genetics
Middle Aged
Mutation
Odds Ratio
Polymerase Chain Reaction
Polymorphism, Genetic
Prospective Studies
Prospective study
Womens health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a nested case control study of 178 incident breast cancer cases and 356 controls in the Atherosclerosis Risk in Communities study. We evaluated the association between breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 gene. After adjustment for height, age at menopause, age at menarche, BMI, HRT, and alcohol intake, carriers of the Val/Leu or Val/Val genotype had a 1.45 fold (95% CI 0.85–2.47) greater odds of breast cancer than Leu/Leu carriers. There was no association of the breast cancer with any individual CYP19 allele. Compared to individuals homozygous with the 167 allele, odds ratios were close to 1.0 for the 167 heterozygous genotype and for the remaining tetranucleotide repeats combined. Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2003.12.009